Xiaoying Mai, age 33, has served on our board of directors since July 2018.
Ms. Mai is an Investment Director of GF Xinde Investment Management Co. Ltd, a venture capital investment firm based in China that specializes in investing in biotechnology companies, a position she has held since June 2015. Ms. Mai
previously served as a financial manager for Guangfa Securities Co., Ltd, a publicly listed company in Hong Kong from December 2012 to June 2015, where she specialized in preparing financial information for public disclosure and tax management.
Ms. Mai has also served as a member of the IPSAS program-international public sector accounting standard and worked with the United Nations in 2011. Ms. Mai holds a B.A. in Business Management from the Guangdong University of Foreign
Studies and a M.A. in accountancy from George Washington University.
Our board of directors believes that Ms. Mai brings extensive
experience in the biotechnology industry and her experience with the Asian markets will help us to expand into such markets, which qualifies her to serve as one of our directors.
Robert Ragusa, age 61, has served on our board of directors since November 2016. Mr. Ragusa is currently the Senior Vice
President, Global Quality and Operations, at Illumina, Inc., a strategic commercial partner of Twist and a publicly traded corporation, where he has worked since December 2013. Prior to joining Illumina, Inc., from April 2010 to November 2013,
Mr. Ragusa was Executive Vice President, Global Operations and Service at Accuray Incorporated, a radiation oncology company that develops, manufactures, sells and supports cancer treatment solutions. Mr. Ragusa holds a B.S. in Biomedical
and Electrical Engineering and an M.B.A. from the University of Connecticut, and an M.S. in Biomedical and Electrical Engineering from Carnegie-Mellon University.
Our board of directors believes that Mr. Ragusa brings extensive experience in important ecosystem partners and managing operations of
large public companies, and this, in addition to his education in biotechnology, finance and management, qualifies him to serve as one of our directors.
Nicolas M. Barthelemy, age 55, has served as a member of our board of directors since October 2019. Mr. Barthelemy brings
over 25 years of industry experience to Twist. From September 2014 to February 2017, Mr. Barthelemy served as the President and Chief Executive Officer of Biotheranostics, Inc., a molecular diagnostics company. Previously, he served as
President, Global Commercial Operations at Life Technologies Corporation, a global life sciences company, which was acquired by Thermo Fisher Scientific Inc. in February 2014. Before Life Technologies, Mr. Barthelemy was with Biogen Inc., a
biotechnology company, most recently as Vice President, Manufacturing. He began his career with Merck & Co., Inc., a pharmaceutical company, as Project Engineer, Vaccine Technology. Mr. Barthelemy currently serves as an advisor to
Warburg Pincus, a private equity firm, in addition to serving as a member of the boards of directors of the following publicly traded companies: Fluidigm Corporation, Repligen Corporation, and 908 Devices Inc. He is also a Director at Biocare
Medical, LLC, a private company. Mr. Barthelemy received an M.S. in chemical engineering from the University of California, Berkeley, and an engineering degree from the Ecole Superieure de Physique et Chimie Industrielles, Paris.
Our board of directors believes that Mr. Barthelemys extensive experience in manufacturing, distributing and commercializing life
science instruments, reagents and services, his knowledge of the research and clinical markets as well as his relevant director experience qualify him to serve as one of our directors.
Keith Crandell, age 60, has served on our board of directors since October 2013. Mr. Crandell has been the Managing Director
of ARCH Venture Corporation, a venture capital firm focused on early-stage technology companies, since 1987. Mr. Crandell is a director of several private companies and he also serves on the board of directors of Quanterix, a publicly traded
life science instrument company and 908 Devices Inc., a publicly traded company specializing in measurement devices for chemical and biochemical analysis. Mr. Crandell previously served as a member of the Board of Directors of Adesto
Technologies Corporation. Mr. Crandell holds a B.S. in Chemistry and Mathematics from St. Lawrence University, an M.S. in Chemistry from the University of Texas, Arlington, and an M.B.A. from the University of Chicago.
Our board of directors believes that Mr. Crandell brings extensive experience in the technology industry and that his service on a number
of boards provides an important perspective on operations, finance and corporate governance matters, which qualifies him to serve as one of our directors.
- 9 -